Cargando…
Abnormally activated OPN/integrin αVβ3/FAK signalling is responsible for EGFR-TKI resistance in EGFR mutant non-small-cell lung cancer
BACKGROUND: Acquired epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) resistance limits the long-term clinical efficacy of tyrosine kinase-targeting drugs. Although most of the mechanisms of acquired EGFR-TKI resistance have been revealed, the mechanism of ~ 15% of cases has not...
Autores principales: | Fu, Yulong, Zhang, Yang, Lei, Zhe, Liu, Ting, Cai, Tingting, Wang, Anqi, Du, Wenwen, Zeng, Yuanyuan, Zhu, Jianjie, Liu, Zeyi, Huang, Jian-an |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7720454/ https://www.ncbi.nlm.nih.gov/pubmed/33287873 http://dx.doi.org/10.1186/s13045-020-01009-7 |
Ejemplares similares
-
Integrin α3/α6 and αV are implicated in ADAM15-activated FAK and EGFR signalling pathway individually and promote non-small-cell lung cancer progression
por: Zhou, Jieqi, et al.
Publicado: (2022) -
The miR-625-3p/AXL axis induces non-T790M acquired resistance to EGFR-TKI via activation of the TGF-β/Smad pathway and EMT in EGFR-mutant non-small cell lung cancer
por: Du, Wenwen, et al.
Publicado: (2020) -
Anlotinib can overcome acquired resistance to EGFR‐TKIs via FGFR1 signaling in non‐small cell lung cancer without harboring EGFR T790M mutation
por: Lian, Zengzhi, et al.
Publicado: (2020) -
CD151 drives cancer progression depending on integrin α3β1 through EGFR signaling in non-small cell lung cancer
por: Zhu, Jianjie, et al.
Publicado: (2021) -
The canonical TGF-β/Smad signalling pathway is involved in PD-L1-induced primary resistance to EGFR-TKIs in EGFR-mutant non-small-cell lung cancer
por: Zhang, Yang, et al.
Publicado: (2019)